Connect Biopharma Holdings Limited (CNTB)
CNTB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1835268/000183526826000013/0001835268-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CNTB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | 2021 |
| SEC CIK | 0001835268 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $64K |
| Net income | -$55.5M |
| Operating income | -$58.1M |
| Net margin | -86687.5% |
| Operating margin | -90740.6% |
| Revenue growth | -99.8% |
| Cash | $38.3M |
| Total assets | $56.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 632.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-12 |
| Cash and burn | $27.0M cash; operating cash flow -$15.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 62,974,309 (2026-07-31); 55,721,657 a year earlier. | Cover page 2026-07-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., New York, New York, United States | PCAOB Form AP 2026-04-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $4.4M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $2.8M | -$17.3M | -$15.9M | $27.0M | No debt tags | $3.0M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $169K | -$19.4M | -$16.0M | $46.0M | No debt tags | $233K | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $0 | -$15.1M | -$11.3M | $38.3M | No debt tags | $64K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $16K | -$17.2M | -$17.4M | $37.8M | No debt tags | $762K | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $48K | -$12.9M | -$12.6M | $40.6M | No debt tags | $2.0M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $0 | -$10.3M | -$10.0M | $47.7M | No debt tags | $26.0M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $698K | -$8.9M | -$2.3M | $78.2M | No debt tags | $26.0M | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $1.2M | -$12.9M | -$13.0M | $97.2M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2026-05-15 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 198 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.1% |
| 1 month | -26.3% |
| 3 months | -73.3% |
| Year to date | -76.0% |
| 1 year | -59.7% |
| From 52-week high | -81.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DWTX | Dogwood Therapeutics Inc. | $1.06 | -8.62% | $40.5M |
| ALDX | Aldeyra Therapeutics Inc. | $0.6696 | +4.01% | $40.4M |
| GANX | Gain Therapeutics Inc. | $0.9402 | -9.60% | $41.9M |
| ELTX | Elicio Therapeutics Inc. | $1.48 | -1.33% | $41.9M |
| IBO | Impact BioMedical Inc. | $4.91 | -4.47% | $42.4M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier